Stereotactic ablative radiotherapy in patients with refractory ventricular tachyarrhythmia. (18th May 2022)

• Record Type: Journal Article
• Authors: Molon, Giulio; Giaj-Levra, Niccolò; Costa, Alessandro; Bonapace, Stefano; Cuccia, Francesco; Marinelli, Alessio; Trachanas, Konstantinos; Sicignano, Gianluisa; Alongi, Filippo
• Is Part Of: European heart journal supplements. Volume 24(2022)Supplement C
• Page Start: C248
• Page End: C253
• Publication Date: 2022-05-18
• Subjects: Ventricular tachycardia -- Arrhythmic storm -- Radiotherapy -- SABR -- Non-invasive EAM; Cardiology -- Periodicals; Cardiology -- Europe -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/suac016
• Languages: English
• ISSNs: 1520-765X

Abstract

Abstract: Stereotactic ablative body radiotherapy (SABR) is an innovative therapeutic approach in patients (pts) with a diagnosis of refractory ventricular tachyarrhythmia (VT) after the use of drugs, radiofrequency catheter ablation, and/or defibrillator (ICD) implant. The current efficacy data of SABR are limited and several prospective clinical studies are ongoing to support the use of ablative radiation dose to control VT. The aim of the current prospective pilot study is to report the efficacy and tolerability of SABR in ICD implanted pts with refractory VT in our centre. Non-invasive electroanatomical mapping (EAM), cardiac computed tomography (CT), and 18 F-fluorodeoxyglucose positron emission (FDG-PET)-CT scan were used and combined with a radiation CT scan. A dose prescription of 25 Gy in a single dose was delivered by volumetric modulated arc therapy (VMAT) Linac-based. The primary endpoint was efficacy, defined as a reduction in ICD shocks after SABR treatment, while the secondary endpoint was safety. Six consecutive pts (five males and one female) implanted with an ICD and with three or more VT were enrolled. One pts died after 1 month, due to end-stage heart failure. Two pts experienced ICD shocks in VT 2 and 5 months after treatment. Three pts experienced no more ICD shocks on VT after therapy. Our data suggest the efficacy and safety of SABR treatment in pts with VT. Larger dataset of pts and longer follow-up are otherwise required to validate the impact of SABR as a standardized treatment in these pts.